Literature DB >> 18487089

Updates on pathogen inactivation of plasma using Theraflex methylene blue system.

Jerard Seghatchian1, Wolfram H Walker, Stefan Reichenberg.   

Abstract

Methylene blue (MB) treated plasma has been in clinical use for 15 years. The current Theraflex MB-Plasma system has a number of improved features compared with the original Springe methodology. This article gives an overview of processing methodology and recent developments, pathogen inactivation capacity, pharmacokinetics and toxicology, effects on plasma proteins and storage stability, clinical experience and future perspectives. Emphasises will be placed on most recent literature and updated information available.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18487089     DOI： 10.1016/j.transci.2008.04.004

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN： 1473-0502            Impact factor:   1.764


  8 in total

Review 1.  Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

Authors:  Americo Cicchetti; Alexandra Berrino; Marina Casini; Paola Codella; Giuseppina Facco; Alessandra Fiore; Giuseppe Marano; Marco Marchetti; Emanuela Midolo; Roberta Minacori; Pietro Refolo; Federica Romano; Matteo Ruggeri; Dario Sacchini; Antonio G Spagnolo; Irene Urbina; Stefania Vaglio; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2016-07       Impact factor: 3.443

2.  Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction.

Authors:  Jerard Seghatchian; Wilhelm G Struff; Stefan Reichenberg
Journal:  Transfus Med Hemother       Date:  2011-01-27       Impact factor: 3.747

3.  Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively.

Authors:  Markus Eickmann; Ute Gravemann; Wiebke Handke; Frank Tolksdorf; Stefan Reichenberg; Thomas H Müller; Axel Seltsam
Journal:  Transfusion       Date:  2018-05-06       Impact factor: 3.157

Review 4.  Methylene blue-treated plasma, versus quarantine fresh frozen plasma, for acute thrombotic thrombocytopenic purpura treatment: Comparison between centres and critical review on longitudinal data.

Authors:  José Luis Arroyo; Eva Martínez; Cristina Amunárriz; Carmen Muñoz; Iñigo Romón; Ignacio Álvarez; José María García
Journal:  Transfus Apher Sci       Date:  2020-04-12       Impact factor: 1.764

5.  Of masks and methylene blue-The use of methylene blue photochemical treatment to decontaminate surgical masks contaminated with a tenacious small nonenveloped norovirus.

Authors:  Constance Wielick; Allyson Fries; Lorène Dams; Ravo M Razafimahefa; Belinda Heyne; Brian H Harcourt; Thomas S Lendvay; Jean-François Willaert; Simon de Jaeger; Eric Haubruge; Etienne Thiry; Louisa F Ludwig-Begall
Journal:  Am J Infect Control       Date:  2022-08       Impact factor: 4.303

6.  Exploring inactivation of SARS-CoV-2, MERS-CoV, Ebola, Lassa, and Nipah viruses on N95 and KN95 respirator material using photoactivated methylene blue to enable reuse.

Authors:  Florine E M Scholte; Kareem B Kabra; Sarah R Tritsch; Joel M Montgomery; Christina F Spiropoulou; Christopher N Mores; Brian H Harcourt
Journal:  Am J Infect Control       Date:  2022-08       Impact factor: 4.303

7.  An Outbreak of Japanese Encephalitis Virus in Australia; What Is the Risk to Blood Safety?

Authors:  Veronica C Hoad; Philip Kiely; Clive R Seed; Elvina Viennet; Iain B Gosbell
Journal:  Viruses       Date:  2022-08-31       Impact factor: 5.818

8.  Effect of Methylene Blue Pathogen Inactivation on the Integrity of Immunoglobulin M and G.

Authors:  Johannes Raster; Kathrin Zimmermann; Jan Wesche; Konstanze Aurich; Andreas Greinacher; Kathleen Selleng
Journal:  Transfus Med Hemother       Date:  2021-02-25       Impact factor: 3.747
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.